Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer

AIM: Some retrospective studies have shown a lack of benefit of 5‐fluorouracil (5‐FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer. Our aim was to assess if this molecular marker can predict benefit from 5‐FU adjuvant chemotherapy. A second objective was t...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jover, R, Zapater, P, Castells, A, Llor, X, Andreu, M, Cubiella, J, Piñol, V, Xicola, R M, Bujanda, L, Reñé, J M, Clofent, J, Bessa, X, Morillas, J D, Nicolás‐Pérez, D, Payá, A, Alenda, C
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2006
Témata:
Colorectal Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1856227/
https://ncbi.nlm.nih.gov/pubmed/16299036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2005.073015
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky